Adenosine receptor signalling in Alzheimer's disease

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Alzheimer's disease (AD) is the leading cause of dementia in older adults, posing significant treatment challenges.
• Current AD treatments do not modify disease progression or fully alleviate cognitive and memory impairments.
• Adenosine G protein-coupled receptors (GPCRs) are emerging as promising therapeutic targets for AD.

Purpose of the Study:

• To review the current literature on Alzheimer's disease.
• To explore the therapeutic potential of adenosine A1 and A2A receptors for AD.
• To discuss novel strategies for drug discovery targeting these receptors.

Main Methods:

• Literature review summarizing research on Alzheimer's disease.
• Analysis of the role of adenosine A1 and A2A receptors in dementia pathogenesis.
• Exploration of preclinical findings on targeting these receptors.

Main Results:

• Adenosine A1 and A2A receptors are present in the human brain and implicated in dementia.
• Preclinical studies show targeting these receptors can reduce beta-amyloid and tau neurotoxicity.
• Improved cognition and memory were observed in preclinical models targeting these receptors.

Conclusions:

• Adenosine A1 and A2A receptors represent a viable therapeutic avenue for Alzheimer's disease.
• Novel strategies like allosterism and targeting receptor oligomers may enhance drug discovery.
• Further research into these targets could lead to more effective dementia treatments.